Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG-Reference-Cited by-同舟云学术

Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG

Published:2005-02-24 Issue:3 Volume:57 Page:444-448
ISSN:0364-5134
Container-title:Annals of Neurology
language:en
Short-container-title:Ann Neurol.

Author:

Leite Maria Isabel,Ströbel Philipp,Jones Margaret,Micklem Kingsley,Moritz Regina,Gold Ralf,Niks Erik H.,Berrih-Aknin Sonia,Scaravilli Francesco,Canelhas Aurea,Marx Alexander,Newsom-Davis John,Willcox Nick,Vincent Angela

Funder

Fundação para a Ciência e a Tecnologia, Portugal

Publisher

Wiley

Subject

Clinical Neurology,Neurology

Reference19 articles.

1. Myasthenia gravis;Drachman;N Engl J Med,1994

2. Unravelling the pathogenesis of myasthenia gravis;Vincent;Nat Rev Immunol,2002

3. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies;Hoch;Nat Med,2001

4. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis;Evoli;Brain,2003

5. Clinical aspects of MuSK antibody positive seronegative MG;Sanders;Neurology,2003

Cited by 212 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Th17 pathway‐related immune signatures in the pathobiology of myasthenia gravis: Integrating the roles of regulatory/effector cytokines and transcription factors;Clinical and Experimental Neuroimmunology;2024-07-08

2. Myasthenia gravis: the future is here;Journal of Clinical Investigation;2024-06-17

3. Acetylcholinesterase inhibitors are ineffective in MuSK-antibody positive myasthenia gravis: Results of a study on 202 patients;Journal of the Neurological Sciences;2024-06

4. MuSK Myasthenia Gravis—Potential Pathomechanisms and Treatment Directed against Specific Targets;Cells;2024-03-21

5. Clinical Features and Prognostic Analysis of MuSK-Antibody-Positive Myasthenia Gravis versus Double-Seropositive Myasthenia Gravis: A Single-Center Study from Central South China;Neuropsychiatric Disease and Treatment;2024-03